Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some things just make you feel all warm and fuzzy inside, don't they?
And that it has come out of no where only to spew. If that doesn't shake those that don't get what the objective is of some here, nothing will.
BMSN, as it has been noted many times, is one of the most solid start-ups out there.
Fear not folks, just look at the name and the image.
Thanks for that, PoPo. You are spot on. I didn't bother to look at the link since I am very familiar with the enforcement and regulations for biologics, vaccines & blood and assumed that was what was being referenced.
For anyone that cares to view the regulations for VBB:
www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073366.htm
Good grief! The company deals with biologics, of course they are going to be heavily regulated. If you find a list that shows they are no longer heavily regulated, start to worry.
Their position in this is current.
Over the past several months I have worked incredibly hard to provide all of the necessary information any investor--especially one looking to invest for more than just a week or so--should need or want to make an informed decision on their investment in BMSN and to a lesser degree, ENTB. Because of this, it can no longer be argued (at least with any legitimacy at all) that BMSN is a shell company or a scam. It can no longer be argued that Koos is a fraud, fleecing his shareholders & squandering all of his gains with no concern for his shareholders. Nor can it be argued that all of the information regarding the science and evidence that the process required to sufficiently contend with the powers-that-be and see the science come to fruition has not been made available, if people were just willing to look.
In these months several changes have occurred and a number of key factors have been confirmed--several PR's updating the shareholders have been released, an update to the Regen website (as modest as it is) has been completed, very important patents that will ultimately dictate the future of the pps have been confirmed, the fact that the GENERATED efficacy data has been submitted to the FDA for hopefully what will be the final submission to them before the approval of HemaXellerate, the fact that HemaXellerate is but ONE of several treatments that will derive form the source HemXellerate, that Koos has put almost 2 million of his own money into this company by way of stock purchases at a PPS much higher than it has been in ages, Min science coupled with the Benitec science will not only target cancer but will teach the body's immune system how to heal itself, etc., etc., etc... The list goes on.
Am I boasting? Though I think I may have earned the right to do so, no I am not. But, I will say that I have done nothing to earn the ridicule, scorn & threats I have received by some and I have worked very hard to provide information and to thwart the false image created of this company. Most know by now by reading my posts that I am more than equipped to handle myself. However, enough is enough is enough.
All that said, all you need to know about your investment in this company is available in the 600 and some odd posts that I have managed to keep active as well as in other dd provided by some. It's all there. Act on it as your conscience and gut dictate.
Very welcome. And to show you just how low they will go:
Trades
0.0033 500,000 13:54:27
0.0033 100,000 13:54:25
0.0032 5,000 13:50:28
0.0033 454,545 13:14:10
0.0033 125,000 13:05:09
Thanks, everyone!
This little "field trip" of ours, whereby we will once and for all confirm the fiscal or calendar question, is confirmed to take place in the very near future. I will complete my full list of questions by the end of the week to pose to the doctors. Please feel free to send any you might have to me at your convenience. And this includes questions about BMSN & ENTB.
Thanks again, everyone.
BMSN
You're very welcome. I do hope you enjoy!
I will update as quickly as I can next week. Perhaps however we will be pleasantly surprised by another Dr. David Koos PR before then.
Thank you.
Hi BF,
I know that it is difficult to grasp the fundamentals of ENTB and the direct connection between ENTB & BMSN due to the lack of information currently present on the ENTB site. However, there is a very strong connection between the two and one that far surpasses that of being companies operated by the same CEO.
It is my intent to provide many, many updates for ENTB upon my return from my visit with Dr. Koos next week. I hope then a significant amount of light will be shed on the current progress of the company.
ENTB
That is an incorrect assumption-- the "30 days" is a no news is good news rule during the initial 30 days of application submission. Since most companies--especially newbies in the world of IND submissions--encounter some form of Q&A during the process, the amount of time required to complete the Q&A is the amount of time required to complete the Q&A. Since it was roughly 30 days for the FDA to return with the first set of questions and roughly 30 days to return with noted satisfaction of answers to said questions but a requested data updated on efficacy, the consensus is that it will be roughly 30 days for them to return their response to the efficacy data.
BMSN
It's not been a "while". It has been roughly five weeks.
Cell treatments ARE regulated differently from chemical drugs. The regulations governing these treatments change rapidly due to the constant updating of information and knowledge obtained with regard to the SUCCESSES versus the many ADVERSE effects of toxic chemical compounds human subjects are exposed to in chemical treatments.
Safety is established much, MUCH faster. Efficacy is established much, MUCH faster. Stem cell treatments have been studied for forty years. HUMAN TRIALS for stem cell therapy have already been PROVED SUCCESSFUL in other countries. Governments all over the world are working vigilantly to fast track applications & assist with making trials as seamless as they should be. There are governments presently working to sign into law ways that will help better coordinate pre clinical with human trials for rapid marketability.
Due to the rapid adoption of major changes within various other governments, the US government are being compelled to change the archaic approach it has in order to allow for rapid market expansion.
BMSN!
BMSN! The future of medicine!
Actually, yes, I know very well how long it takes to go from IND to marketability of a pharmaceutical. BEEN IN THE BUSINESS FOR A NUMBER OF YEARS.
There is a great demand on the FDA by very vocal and established cancer foundations to work harmoniously with companies offering alternative treatments for cancer. ESPECIALLY STEM CELL AND GENE SILENCING.
WHEN FDA APPROVES the IND, you can bet BP will be on board very fast. And with orphan drug status the time from IND through trials can be as little as 90 days!
BMSN
BMSN .0032 POISED TO BUST INTO THE $TRILLION PHARMA SCENE ANY DAY NOW!
Regen Biopharma, Subsidiary of Bio-Matrix Scientific Group is that much closer to the US FDA's Orphan Drug approval to begin clinical trials for their Trademark autologous (patient derives) stem cell treatment HemaXellerate for Aplastic Anemia.
HemaXellerate is just one of several proposed treatments from the patented HemXellerate approach to combating life threatening diseases.
And if teaching a patient's body to attack deadly intruders by way of their own stem cells is not out-of-this-world, try this on for size:
siRNA GENE SILENCING: In a nutshell, Dr. Wei-Ping Min, long-time friend of & mentor to Dr. Thomas Ichim, CSO of Regen Biopharma, has developed a process whereby the genetic components contributing to the growth of cancer are silenced.
But, they are not stopping there--the latest licensing deal with Benitec Australia coupled with Dr. Min's siRNA science not only will tell cancer to shut up and get the bleep out, but will also help to give a mega boost to the patients immune system.
Oh, and the patented treatments have world-wide protection.
CAN YOU SAY CHA-CHING?
BIG PHARMA AND THEIR DEEP POCKETS ARE WATCHING!
Bio-Matrix Scientific Group:
-----Fully Reporting
-----Totally Transparent
-----Comprised of world renowned scientists considered leaders in the world of stem cell medicine & gene silencing
-----Aggressively pursuing their position in a trillion dollar pharmaceutical market while at the same time working just as hard to improve quality of life!
-----NO DUMPING OF SHARES BY THE COMPANY CEO REGARDLESS OF WHAT SOME WILL HAVE YOU THINK!
BMSN--a steal @ 0032. A price that is soon to be but a very distant memory!
SAN DIEGO, CA--(Marketwired - Aug 16, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN.
"The operating objective of Regen BioPharma is to identify, develop, and commercialize intellectual property which has demonstrated preclinical efficacy, and addresses significant markets," said David Koos, CEO of Regen BioPharma.
Current day cancer immunotherapy is based on stimulating immune responses to cancer cells. Unfortunately, in the majority of patients, the tumor reduces ability of the immune response to kill the tumor resulting in reduced efficiency of many prior cancer vaccines.
By blocking the mechanisms by which the tumor escapes from the immune response, several companies have developed successful cancer drugs, for example, Bristol-Myers Squibb, which developed Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab blocks the immune inhibitory molecule CTLA-4, which results in augmentation of immune responses.
"Regen's approach, which is currently in late-stage preclinical testing, involves blocking the immune suppressive gene IDO, while concurrently using dendritic cells to stimulate the immune system," said Dr. Thomas Ichim, Chief Scientific Officer for Regen BioPharma. "Through the combination approach, and based on the published data, we are hoping to offer a new weapon in the fight against breast cancer."
Regen BioPharma is currently conducting toxicology experiments on its therapeutic approach, with anticipated FDA filing in the 4th Quarter of 2013.
References
1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46.
3. www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
BMSN .0032 POISED TO BUST INTO THE $TRILLION PHARMA SCENE ANY DAY NOW!
Regen Biopharma, Subsidiary of Bio-Matrix Scientific Group is that much closer to the US FDA's Orphan Drug approval to begin clinical trials for their Trademark autologous (patient derives) stem cell treatment HemaXellerate for Aplastic Anemia.
HemaXellerate is just one of several proposed treatments from the patented HemXellerate approach to combating life threatening diseases.
And if teaching a patient's body to attack deadly intruders by way of their own stem cells is not out-of-this-world, try this on for size:
siRNA GENE SILENCING: In a nutshell, Dr. Wei-Ping Min, long-time friend of & mentor to Dr. Thomas Ichim, CSO of Regen Biopharma, has developed a process whereby the genetic components contributing to the growth of cancer are silenced.
But, they are not stopping there--the latest licensing deal with Benitec Australia coupled with Dr. Min's siRNA science not only will tell cancer to shut up and get the bleep out, but will also help to give a mega boost to the patients immune system.
Oh, and the patented treatments have world-wide protection.
CAN YOU SAY CHA-CHING?
Bio-Matrix Scientific Group:
-----Fully Reporting
-----Totally Transparent
-----Comprised of world renowned scientists considered leaders in the world of stem cell medicine & gene silencing
-----Aggressively pursuing their position in a trillion dollar pharmaceutical market while at the same time working just as hard to improve quality of life!
BMSN--a steal @ 0032. A price that is soon to be but a very distant memory!
SAN DIEGO, CA--(Marketwired - Aug 16, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN.
"The operating objective of Regen BioPharma is to identify, develop, and commercialize intellectual property which has demonstrated preclinical efficacy, and addresses significant markets," said David Koos, CEO of Regen BioPharma.
Current day cancer immunotherapy is based on stimulating immune responses to cancer cells. Unfortunately, in the majority of patients, the tumor reduces ability of the immune response to kill the tumor resulting in reduced efficiency of many prior cancer vaccines.
By blocking the mechanisms by which the tumor escapes from the immune response, several companies have developed successful cancer drugs, for example, Bristol-Myers Squibb, which developed Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab blocks the immune inhibitory molecule CTLA-4, which results in augmentation of immune responses.
"Regen's approach, which is currently in late-stage preclinical testing, involves blocking the immune suppressive gene IDO, while concurrently using dendritic cells to stimulate the immune system," said Dr. Thomas Ichim, Chief Scientific Officer for Regen BioPharma. "Through the combination approach, and based on the published data, we are hoping to offer a new weapon in the fight against breast cancer."
Regen BioPharma is currently conducting toxicology experiments on its therapeutic approach, with anticipated FDA filing in the 4th Quarter of 2013.
References
1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46.
3. www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
Just a friendly reminder about the platform technology and understanding that it is all relative:
ENTB
ENTB
And further to what Inventor has said, as it has been shown many times, Dr. Koos has purchased nearly 2 million dollars worth of shares with his own money, at a pps much, much higher than it is right now.
He is very committed to this company and seeing it successful. For him to "dump" a billion shares or ANY number of shares that would cause a major declination of the pps would be completely illogical, indicative of someone with no business sense and tantamount to professional suicide.
Dr. Koos does not operate like that. He is looking for BMSN to grow not stagnate.
BMSN!
Aha! I forgot about that. Thank you, oh wise man of few words!
BMSN
You're cracking me up with your accumulation, PP. You keep it up, you'll be able to buy all of we longs a stretch limo.
BMSN!
OOOOOPS! What in the world happened there?
****"don't their homework"
SHOULD READ: they have done their homework!!!
I know you all know that.
BMSN
Something very significant I keep forgetting to post:
The approximate cost of securing the patents, from beginning to end, at minimum, is $30,000 PER. That means, for every patent that BMSN has secured or is in the process of securing, the associated costs are at least $30,000. You don't spend that kind of money unless you have a great deal of confidence in your purchase.
OK, some do. But not this company. It is alllllll there, in black & white.
BMSN.
I concur. And, thank you.
Look! I don't need that kind of pressure--I am operating on 1/16th of a brain cell now as it is. But, thank you.
I do have the utmost confidence in the science and the doctors. I really cannot find any reason why they should not be approved for trials and subsequently successful. It's all there. They have don't their homework. And plenty of it.
I, too, am very excited. I wish I could look into a crystal ball and find a definitive. But, I will settle for waiting with bated breath as I continue to edumacate myself on what these doctors have been doing all these years. Pretty darn awesome.
BMSN!
From the 31 July PR:
During my 17 July conversation with Dr. Thomas Ichim he was pretty adamant in conveying his confidence that Regen had satisfied the FDA's requirements with the most recent submission of information for what was the second round of Q&A. Since Dr. Ichim is in fact da man in stem cell research, not gonna question the validity of his confidence or ability to adequately provide research information.
So...21 June they received a request for more efficacy data. Sometime between 21 June (because I believe them to be workaholics, too) and spproximately 5:15 EST 17 July, data relating to the below had already been submitted (as per my conversation with the good Dr.):
There was a 14 day pre-clinical study required to generate the submitted data. Let's say because they are workaholics they initiated the study on Saturday, 22 June. Thus it would have concluded on 6 July.
Judging by my own observations with respect to how efficient the Regen team can be (and that's pretty darn efficient, let me tell you.) coupled with what I know can be part of the process of transferring scientific findings into a government approved format, the submission would have been between Wednesday, 10 July and Monday, 15 July.
If the submission requirement mandates snail mail, the data would have been received the next day via overnight delivery. If electronic, the same day of course.
It is my firm belief that the company has to await written confirmation by the FDA before proceeding. I do not believe the 30 day "no news is good news" is applicable when there is Q&A (remember Q&A is very much normal and present with the vast majority of submissions). That being said, if in fact during the course of considering the efficacy data submitted, the FDA does not generate more questions based on their lack of knowledge in stem cell research (and compared to stem cell researches, there is A LOT the FDA does not know) then I would have to say the decision or follow-up Q&A was determined Wednesday or Thursday passed.
This is just what I have come up with based on my experience in all this. As great as it would be to see an approval PR tomorrow morning BEFORE the market opens, I won't fret for I believe we will have it when it is meant to be had.
BMSN
I know PP, I know.
There was nothing "fluff" about that PR--"fluff" is only applicable when you are talking about companies who have nothing, no intentions of ever having anything and intend to deceive investors as long as they possibly can. Dr. Koos needs not buy anymore time--he has spelled out from the beginning the projected path and it is as plain as day on the timeline.
The PR was a reiteration that they are on schedule and that they are making progress in current pre-clinical trials for the next IND application.
The 30 day approval myth was created by members of this board based on public information that actually should be removed since it lacks some very real and common caveats. That myth was disseminated all over the place in various ways, in multiple languages. The hype created a frenzy and when what was never to be to begin with, wasn't delivered, another frenzy was created. Blame, lies & accusations ensued and people continued to dump their shares, further assisting the brutalization of this sub-penny stock.
Typical human behavior. As sad a reality as that is.
There was nothing fluff about that PR. That PR was a message to the shareholders that the company intends to keep them abreast of all that is transpiring to the best of their ability. There is nothing to mention of Hema that hasn't already been said. They are in wait mode. It is as simple as that. We were made aware of this by Dr. Koos not too long ago already.
BMSN
Yes they do and yes they will; within three or four days the PR must be released whether they are denied or approved.
BMSN
Well, I just choked on my wine!
It does take time--the FDA did not get to where they are with regulations and complicating lives over night. And you must remember, not only is the approach Regen is taking new, so are the treatments when you consider that we have been at the mercy of pharmacology for how long?
These treatments are new. The FDA and other governmental entities really haven't grasped them in their entirety. Questions will be asked. You must remember, that we as a nation, forbade the funding of stem cell research for a very long time. We still do in many ways. These ventures have been private and on the "down low" as it were. But, they have been legitimate and fruitful nonetheless.
And gene silencing-- Oh my goodness! Teaching the body to heal itself and turning off the nasty stuff as they attack...that was sci-fi when I was a kid. Much like talking to someone on a computer. But do not doubt that it is not the future. And don't doubt that they are not proceeding as they should to see it all come to fruition. There are hurdles though. There always are.
BMSN
That was a wee bit intense. Looks like someone is needing a day off.
Besides, you and I both know it is when the Min Science IND is approved that all hell is really going to break loose. Can you imagine it...Hema in the throes of trials and looking mighty fine with data then Min IND is approved??? Oh my goodness! Oh my goodness!
BMSN
I am not evading the question. I am waiting to see if a couple of people respond with thumping of the chests explanations. If not, I will provide examples.
BMSN
BMSN UPDATE: GETTING POISED FOR GENE SILENCING IND SUBMI$$ION:
SAN DIEGO, CA -- (Marketwired) -- 08/16/13 -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN.
"The operating objective of Regen BioPharma is to identify, develop, and commercialize intellectual property which has demonstrated preclinical efficacy, and addresses significant markets," said David Koos, CEO of Regen BioPharma. "On May 6, 2013, we acquired issued patent # 8,389,708 from Dr. Wei-Ping Min of the University of Western Ontario, as well as proprietary know-how covering means of inducing immune mediated killing of melanoma and breast cancer. This data has been published in two peer-reviewed scientific publications (1, 2). Last week, we licensed from Benitec Australia Ltd rights to patented biological mechanisms that control the gene manipulation processes. These processes dovetail into the Wei-Ping Min technology to induce regression of cancer. We believe that the combination of these patents provide us international patent coverage for development of this technology into clinical trials and eventually as a non-toxic alternative to current day chemotherapy and radiotherapy."
Current day cancer immunotherapy is based on stimulating immune responses to cancer cells. Unfortunately, in the majority of patients, the tumor reduces ability of the immune response to kill the tumor resulting in reduced efficiency of many prior cancer vaccines.
By blocking the mechanisms by which the tumor escapes from the immune response, several companies have developed successful cancer drugs, for example, Bristol-Myers Squibb, which developed Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab blocks the immune inhibitory molecule CTLA-4, which results in augmentation of immune responses.
"Regen's approach, which is currently in late-stage preclinical testing, involves blocking the immune suppressive gene IDO, while concurrently using dendritic cells to stimulate the immune system," said Dr. Thomas Ichim, Chief Scientific Officer for Regen BioPharma. "Through the combination approach, and based on the published data, we are hoping to offer a new weapon in the fight against breast cancer."
Regen BioPharma is currently conducting toxicology experiments on its therapeutic approach, with anticipated FDA filing in the 4th Quarter of 2013.
References
1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46.
3. www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.